


Figure S1. Data analysis



^a Fulvestrant was given once every 4 weeks with one additional dose 2 weeks after the initial dose
^b Survival follow-up data to be collected until 1 year after final data analysis data-cutoff data or until all patients discontinued treatment, whichever comes first.
^c Final analysis planned after ≥90 PFS events, including ≥50 events from *FGF*-amplified patients.
FGF, fibroblast growth factor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PFS, progression-free survival.